You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Moderna to develop single-dose booster shot for Covid-19 and flu

US drug maker Moderna has announced the development of a single-dose vaccine candidate that is a combination of a Covid-19 booster as well as a seasonal flu jab.

Topics
Coronavirus Vaccine | Coronavirus | Flu

IANS  |  Washington 

Moderna
Moderna Covid-19 vaccination

US drug maker Moderna has announced the development of a single-dose vaccine candidate that is a combination of a Covid-19 booster as well as a seasonal jab.

"We believe our mRNA platform can solve the world's greatest health challenges, from diseases impacting millions, to ultra-rare diseases impacting dozens, to medicines personalised down to the individual level," CEO Stephane Bancel said.

"Today we are announcing the first step in our novel respiratory vaccine programme with the development of a single dose vaccine that combines a booster against Covid-19 and a booster against flu," she added.

The combination vaccine mRNA-1073 encodes for the Covid-19 spike protein and the hemagglutinin glycoproteins.

Moderna is developing vaccines against viral diseases including vaccines against acute respiratory infections, vaccines against persistent infections, as well as vaccines against threats to global public health.

"We are making progress on enrolling patients in our rare disease programmes, and we are fully enrolled in our personalised cancer vaccine trial. We believe this is just the beginning of a new age of information-based medicines," Bancel said.

The US drug maker has, last week, applied to the US Food and Drug Administration (FDA) for the evaluation of a booster dose of its mRNA-based Covid-19 vaccine.

Early trials have shown that the mRNA-1273 booster shot at 50 microgram dose level induced robust antibody responses of more than 40 times against the highly infectious Delta variant (B.1.617.2), the company has said.

The US regulatory body had authorised the emergency use of the Moderna's Covid-19 vaccine in individuals 18 years of age or older in December, 2020. It has received emergency authorisation for use of its Covid-19 vaccine in adults from health agencies in more than 50 countries.

The Moderna Covid-19 vaccine is an mRNA vaccine against Covid-19 encoding for a prefusion stabilised form of the Spike (S) protein.

--IANS

rvt/vd

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, September 10 2021. 19:28 IST
RECOMMENDED FOR YOU